Intellia Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
NTLA$12.11+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(Amounts in thousands except share and per share data)
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $226,748 | $523,506 |
| Marketable securities | 685,475 | 669,116 |
| Accounts receivable ($0.2 million and $0.3 million, respectively, from related party) | 36,456 | 3,768 |
| Prepaid expenses and other current assets | 49,651 | 20,407 |
| Total current assets | 998,330 | 1,216,797 |
| Marketable securities - noncurrent | 99,864 | 69,338 |
| Property and equipment, net | 32,760 | 27,921 |
| Operating lease right-of-use assets | 115,375 | 133,076 |
| Equity method investment | 11,765 | 32,455 |
| Investments and other assets | 42,883 | 40,527 |
| Total Assets | $1,300,977 | $1,520,114 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable | $7,452 | $5,154 |
| Accrued expenses ($1.0 million and $1.6 million, respectively, from related party) | 67,017 | 60,876 |
| Current portion of operating lease liability | 18,599 | 16,685 |
| Current portion of deferred revenue ($0 and $19.9 million, respectively, from related party) | 22,140 | 43,839 |
| Total current liabilities | 115,208 | 126,554 |
| Deferred revenue, net of current portion | 38,853 | 19,932 |
| Long-term operating lease liability | 96,747 | 114,018 |
| Contingent consideration liability | - | 24,026 |
| Total liabilities | 250,808 | 284,530 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.0001 par value; 240,000,000 and 120,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 92,997,158 and 87,103,007 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 9 | 9 |
| Additional paid-in capital | 2,710,797 | 2,420,223 |
| Accumulated other comprehensive loss | (2,258) | (7,461) |
| Accumulated deficit | (1,658,379) | (1,177,187) |
| Total stockholders’ equity | 1,050,169 | 1,235,584 |
| Total Liabilities and Stockholders’ Equity | $1,300,977 | $1,520,114 |
INTELLIA THERAPEUTICS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.